Semaglutide Approved for Treatment of Metabolic Dysfunction–Associated Steatohepatitis with Fibrosis

Approval was based on improvement on serial liver biopsies.

In August 2025, the U.S. Food and Drug Administration approved injectable semaglutide 2.4 mg (Wegovy) for the treatment of noncirrhotic metabolic dysfunction–associated steatohepatitis (MASH; formerly known as nonalcoholic steatohepatitis) in adults with moderate-to-advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). The drug was previously approved at the same dose for the treatment of obesity.

Context

MASH is typically managed with lifestyle changes (focused on weight reduction and alcohol avoidance) and treatment of diabetes and hyperlipidemia (for patients with those disorders). However, a growing body of evidence has suggested that glucagon-like peptide-1 (GLP-1)–receptor agonists such as semaglutide can delay or reverse …

Authors

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Semaglutide Approved for Treatment of Metabolic Dysfunction–Associated Steatohepatitis with Fibrosis

Related Content

Topics

Context

Authors